Skip to main content
Sign In
 

Clinical Trials


Study of the Safety & Efficacy of Leukine® in the Treatment of Alzheimer’s Disease

Purpose – to examine the safety and efficacy of the study drug, Sargramostim (Leukine®) on memory in adults with Mild-to-Moderate Alzheimer’s Disease.

 

See more at clinicaltrials.gov
A medicine that is FDA-approved for bone marrow stimulation (called Leukine®/sargramostim) will be tested for its ability to be tolerated by Alzheimer's disease patients and potentially to improve their memory.



To learn more about the research that led to the Leukine® clinical trial, please click on these links:

  • GM-CSF upregulated in rheumatoid arthritis reverses cognitive impairment and amyloidosis in Alzheimer mice
  • Granulocyte Macrophage Colony Stimulating Factor Treatment is Associated with Improved Cognition in Cancer Patients

 

EMERGE – Phase 3 Study of Aducanumab in Early Alzheimer’s Disease

The EMERGE study is a global study assessing the efficacy and safety of an investigational medication, to determine whether it can slow the progression of symptoms in early Alzheimer’s disease.

 

See more at clinicaltrials.gov
The primary objective of the study is to evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score as compared with placebo in participants with early AD. Secondary objectives are to assess the effect of monthly doses of aducanumab as compared with placebo on clinical progression as measured by Mini-Mental State Examination (MMSE), AD Assessment Scale-Cognitive Subscale (13 items) [ADAS-Cog 13], and AD Cooperative Study-Activities of Daily Living Inventory (Mild Cognitive Impairment version) [ADCS-ADL-MCI].